Concomitant tuberculosis and aspergillosis in patients with COVID-19: a case report
-
Elahe Sasani
,
Sadegh Khodavaisy
,
Mohammadreza Salehi
,
Sareh Bagheri-Josheghani
,
Mahsa Abdorahimi
,
Seyed Ali Dehghan Manshadi
,
Alireza Abdollahi
,
Amir Salami
,
Marjan Sohrabi
,
Arezoo Salami Khaneshan
Abstract
Coexisting pulmonary aspergillosis and tuberculosis in a post-COVID-19 patient is rare. Here, we are going to report a case of combined pulmonary aspergillosis and tuberculosis in a 51-year-old female who was previously diagnosed with COVID-19 pneumonia. The patient was treated with voriconazole and anti-tuberculosis agents.
1. Divangahi M. The new paradigm of immunity to tuberculosis. Springer 2013.
2. Nguyen NTB, Le Ngoc H, Nguyen NV, Dinh LV, Nguyen HV, Nguyen HT, et al. Chronic pulmonary Aspergillosis situation among post tuberculosis patients in Vietnam: an observational study. J Fungi (Basel) 2021; 7: 532.
3. Teng G-L, Huang Q, Xu L, Chi JY, Wang C, Hu H. Clinical features and risk factors of pulmonary tuberculosis complicated with pulmonary aspergillosis. Eur Rev Med Pharmacol Sci 2022; 26: 2692-2701.
4. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan) 2021; 13: 5.
5. Salehi M, Ahmadikia K, Badali H, Khodavaisy S. Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. Mycopathologia 2020; 185: 607-611.
6. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PloS One 2021; 16(5): e0251170.
7. Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med 2011; 184: 1076-1084.
8. Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol 2020; 104: 7777-7785.
9. Musso M, Di Gennaro F, Gualano G, Mosti S, Cerva C, Fard SN, et al. Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy. Infection 2021; 49 : 1061-1064.
10. Dissanayake HA, Weeratunga PN, Karunanayake P, Lanerolle RD, Chandu de Silva MV, Jayasinghe S. Embolizing pulmonary aspergillosis, mycobacterial & aspergillous splenic abscess and cytomegalovirus co-infection following steroid induced immunosuppression: a case report. BMC Infect Dis 2018; 18: 367.
11. Maghrabi F, Denning DW. The management of chronic pulmonary aspergillosis: the UK national aspergillosis centre approach. Curr Fungal Infect Rep 2017; 11: 242-251.
12. Rali P, Veer M, Gupta N, Singh AC, Bhanot N. Opportunistic pulmonary infections in immunocompromised hosts. Crit Care Nurs Q 2016; 39: 161-175.
13. Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta‐analysis: liver manifestations and outcomes in COVID‐19. Aliment Pharmacol Ther 2020; 52: 584-599.
14. Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H, et al. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses 2021; 64: 798-808.
15. Vidanapathirana M, Minuvanpitiya G, Karunaratne R, Fernando A. Triple infection with disseminated tuberculosis, invasive aspergillosis and COVID-19 in an organ transplant recipient with iatrogenic immunosuppression. BMJ Case Rep 2021; 14(8): e245131.
16. Gandotra A, Mehtani R, Premkumar M, Duseja A, De A, Mallik N, et al. Invasive pulmonary Aspergillosis and tuberculosis complicated by Hemophagocytic Lymphohistiocytosis-sequelae of COVID-19 in a liver transplant recipient. J Clin Exp Hepatol 2022; 12: 1007-1011.
17. Vaideeswar P, Prasad S, Deshpande JR, Pandit SP. Invasive pulmonary aspergillosis: A study of 39 cases at autopsy. J Postgrad Med 2004; 50: 21-26.
18. Gefter WB. The spectrum of pulmonary aspergillosis. J Thorac Imaging 1992; 7: 56-74.
19. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71: 1367-1376.
20. Jalandra R, Babu A, Dutt N, Chauhan NK, Bhatia P, Nag VL, et al. Co-infections in Hospitalized COVID-19 patients-A prospective observational study. Cureus 2022; 14(10): e30608.
21. Fehér Á, Szarvas Z, Lehoczki A, Fekete M, Fazekas-Pongor V. Co-infections in COVID-19 patients and correlation with mortality rate. Minireview. Physiol Int 2022; 10.1556/2060.2022.00015.
2. Nguyen NTB, Le Ngoc H, Nguyen NV, Dinh LV, Nguyen HV, Nguyen HT, et al. Chronic pulmonary Aspergillosis situation among post tuberculosis patients in Vietnam: an observational study. J Fungi (Basel) 2021; 7: 532.
3. Teng G-L, Huang Q, Xu L, Chi JY, Wang C, Hu H. Clinical features and risk factors of pulmonary tuberculosis complicated with pulmonary aspergillosis. Eur Rev Med Pharmacol Sci 2022; 26: 2692-2701.
4. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan) 2021; 13: 5.
5. Salehi M, Ahmadikia K, Badali H, Khodavaisy S. Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. Mycopathologia 2020; 185: 607-611.
6. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PloS One 2021; 16(5): e0251170.
7. Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med 2011; 184: 1076-1084.
8. Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol 2020; 104: 7777-7785.
9. Musso M, Di Gennaro F, Gualano G, Mosti S, Cerva C, Fard SN, et al. Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy. Infection 2021; 49 : 1061-1064.
10. Dissanayake HA, Weeratunga PN, Karunanayake P, Lanerolle RD, Chandu de Silva MV, Jayasinghe S. Embolizing pulmonary aspergillosis, mycobacterial & aspergillous splenic abscess and cytomegalovirus co-infection following steroid induced immunosuppression: a case report. BMC Infect Dis 2018; 18: 367.
11. Maghrabi F, Denning DW. The management of chronic pulmonary aspergillosis: the UK national aspergillosis centre approach. Curr Fungal Infect Rep 2017; 11: 242-251.
12. Rali P, Veer M, Gupta N, Singh AC, Bhanot N. Opportunistic pulmonary infections in immunocompromised hosts. Crit Care Nurs Q 2016; 39: 161-175.
13. Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta‐analysis: liver manifestations and outcomes in COVID‐19. Aliment Pharmacol Ther 2020; 52: 584-599.
14. Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H, et al. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses 2021; 64: 798-808.
15. Vidanapathirana M, Minuvanpitiya G, Karunaratne R, Fernando A. Triple infection with disseminated tuberculosis, invasive aspergillosis and COVID-19 in an organ transplant recipient with iatrogenic immunosuppression. BMJ Case Rep 2021; 14(8): e245131.
16. Gandotra A, Mehtani R, Premkumar M, Duseja A, De A, Mallik N, et al. Invasive pulmonary Aspergillosis and tuberculosis complicated by Hemophagocytic Lymphohistiocytosis-sequelae of COVID-19 in a liver transplant recipient. J Clin Exp Hepatol 2022; 12: 1007-1011.
17. Vaideeswar P, Prasad S, Deshpande JR, Pandit SP. Invasive pulmonary aspergillosis: A study of 39 cases at autopsy. J Postgrad Med 2004; 50: 21-26.
18. Gefter WB. The spectrum of pulmonary aspergillosis. J Thorac Imaging 1992; 7: 56-74.
19. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71: 1367-1376.
20. Jalandra R, Babu A, Dutt N, Chauhan NK, Bhatia P, Nag VL, et al. Co-infections in Hospitalized COVID-19 patients-A prospective observational study. Cureus 2022; 14(10): e30608.
21. Fehér Á, Szarvas Z, Lehoczki A, Fekete M, Fazekas-Pongor V. Co-infections in COVID-19 patients and correlation with mortality rate. Minireview. Physiol Int 2022; 10.1556/2060.2022.00015.
| Files | ||
| Issue | Vol 16 No 3 (2024) | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/ijm.v16i3.15800 | |
| Keywords | ||
| Pulmonary; Aspergillosis; Tuberculosis; COVID-19; Coinfection | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Sasani E, Khodavaisy S, Salehi M, Bagheri-Josheghani S, Abdorahimi M, Dehghan Manshadi SA, Abdollahi A, Salami A, Sohrabi M, Salami Khaneshan A. Concomitant tuberculosis and aspergillosis in patients with COVID-19: a case report. Iran J Microbiol. 2024;16(3):428-433.
